High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects

Journal of Medical Genetics

Volumn 36, Issue 4, 1999, Pages 304-308

  Goelen, G ^a   Teugels, E ^a   Bonduelle, M ^a   Neyns, B ^a   De Greve J ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

BRCA genes; Breast cancer; Ovarian cancer; Predictive testing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BELGIUM; BREAST CANCER; FAMILY; FEMALE; GENETIC COUNSELING; HUMAN; MUTATION RATE; OVARY CANCER; PEDIGREE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; BELGIUM; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHROMOSOME MAPPING; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; PHENOTYPE; TRANSCRIPTION FACTORS;

EID: 0032945069     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Easton FD, Ford D, Bishop DT, the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 -mutation carriers. Am J Hum Genet 1995;56:265-71.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
3. Ford D, Easton DF, The genetics of breast and ovarian cancer. Br J Cancer 1995;72:805-12.
4. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:10-14.
5. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
6. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378: 789-92.
7. Lerman C, Rimer BK, Engstrom PF. Cancer risk notification: psychosocial and ethical implications. J Clin Oncol 1991;9:1275-82.
8. Kash KM, Holland JC, Halper MS, Miller GM. Psychological distress and surveillance behaviors of woman with a family history of breast cancer. J Natl Cancer Inst 1992;84: 24-30.
9. Biesecker BB, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993;269:1970-4.
10. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994;271:785.
11. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994;44: 1533-6.
12. Ponder BAJ. Setting up and running a familial cancer clinic. Br Med Bull 1994;50:732-45.
13. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997;336: 823-7.
14. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer II. BRCA1 and BRCA2. JAMA 1997;277: 997-1003.
15. Geller G, Botkin JR, Green MJ, et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA 1997;277:1467-74.
16. Hartmann L, Jenkins R, Schaid D, Yang P. Prophylactic mastectomy: preliminary retrospective cohort analysis. In: Proceedings of the 88th Annual Meeting of the American Association for Cancer Research, 12-16 April 1997. San Diego, CA: AACR, 1997:168.
17. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336:1465-71.
18. Hogervorst FBL, Cornelis RS, Bout M, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208-12.
19. Futreal PA, Liu Q, Schattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
20. Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 1997;17:341-5.
21. Peelen T, van Vliet M, Petrij-Bosch A, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997;60:1041-9.
22. Puget N, Torchard D, Serova-Sinilnikova OM, et al. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 1997;57:828-31.
23. Swensen J, Hoffman M, Skolnick MH, Neuhausen SL. Identification of a 14 kb deletion involving the promotor region of BRCA1 in a breast cancer family. Hum Mol Genet 1997;6:1513-17.
24. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409-15.
25. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing JAMA 1997;278:1242-50.
26. Hamann U, Häner M, Stosiek U, Bastert G, Scott RJ. Low frequency of BRCA germline mutations in 45 German breast/ovarian cancer families. J Med Genet 1997;34:884-8.
27. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-5.